Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.34971
Abstract: Key Points Question What is the difference in 10-year restricted mean survival time when receiving a kidney transplant versus remaining on the wait list and continuing dialysis for transplant-eligible patients with kidney failure across different… read more here.
Keywords: eligible patients; dialysis; patients kidney; kidney failure ... See more keywords
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6114
Abstract: BACKGROUND Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies. METHOD Herein, we performed a retrospective… read more here.
Keywords: cell; rituximab bendamustine; cell lymphoma; bendamustine cytarabine ... See more keywords
Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13821
Abstract: This non‐interventional observational study described the current standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment… read more here.
Keywords: care transplant; standard care; diagnosed multiple; newly diagnosed ... See more keywords
Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.1182/blood.v128.22.1141.1141
Abstract: This is a phase 2 dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma. The results of 4 dose levels are… read more here.
Keywords: dexamethasone induction; induction consolidation; transplant eligible; consolidation ... See more keywords
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000526
Abstract: Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a… read more here.
Keywords: outcomes s1106; year; five year; year outcomes ... See more keywords
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022007371
Abstract: The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively… read more here.
Keywords: rituximab; transplant eligible; chop dhap; response ... See more keywords
Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Management and Research"
DOI: 10.2147/cmar.s138932
Abstract: Objective The aim of this study was to compare the early efficacy and survivals of induction regimens for transplant-eligible patients with untreated multiple myeloma. Materials and methods A comprehensive literature search in electronic databases was… read more here.
Keywords: multiple myeloma; eligible patients; induction; transplant eligible ... See more keywords
The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.00676
Abstract: As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge… read more here.
Keywords: myeloma; treatment; multiple myeloma; non transplant ... See more keywords